In an interconnected pricing world, a decision in one market can echo far beyond its borders. For health economics and outcomes research (HEOR) and health technology assessment (HTA) leaders, Most Favored Nation (MFN) and international reference pricing (IRP) are raising the stakes for how value is demonstrated, recognised, and sustained.